Blueprint Medicines nabs 4th approval in bid toward profitability
Blueprint Medicines’ push to profitability continues.
On Wednesday, the Cambridge biotech announced the FDA approved its longtime lead drug, Ayvakit, for advanced systemic mastocytosis, a group of debilitating rare diseases where one type of immune cell — mast cells — builds up uncontrollably in a particular organ. The decision came on the heels of Phase III trials showing that more than half of late-stage patients who received the drug responded to it and did so for just over three years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.